WeGuide Pty Ltd

Based in Australia, WeGuide Pty Ltd, operates as a patient engagement and clinical research management software provider. Based in Parkville, Australia and founded in 2019, WeGuide Pty Ltd offers software solutions for patient engagement and clinical research management. The company raised AUD 1. 9 million in Grant funding in August 2026 from new investor CUREator+.

This funding will support the development of a platform that simplifies the creation of digital biomarkers and a mobility recovery biomarker in collaboration with Neuroscience Research Australia. WeGuide offers a comprehensive patient management platform specifically designed for clinical trials and research operations. The platform includes functionalities for patient data collection, automated study management, and enhanced patient engagement through digital health solutions. It is utilized by clinical research organizations, research institutions, and healthcare clinics globally, impacting over 200,000 patients.

The system optimizes patient participation and data quality, addressing challenges in clinical research. WeGuide's customizable solutions are ready for deployment within weeks, facilitating clinical tasks like eConsent, patient registries, and telehealth services across diverse markets. WeGuide’s revenue generation model is based on subscription plans and partnerships with healthcare institutions, research organizations, and clinical research organizations. The business engages in direct-to-business transactions, providing digital health solutions that streamline clinical trial processes and enhance patient engagement.

Clients benefit from features like customizable patient engagement applications and integration with wearable devices for real-time data capture. Pricing structures are tailored based on deployment scale and service features, reflecting the platform's modular design. The company plans to develop a platform that simplifies the creation of digital biomarkers, making the process faster and cheaper. Current initiatives include supporting the development of a mobility recovery biomarker in collaboration with Neuroscience Research Australia.